Complement Factor I (CFI) is a critical soluble serine protease that serves as a master regulator of the complement alternative pathway. By cleaving C3b and C4b in the presence of cofactors, CFI prevents runaway complement activation. Dysregulation of CFI is directly implicated in geographic atrophy (GA) secondary to age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and C3 glomerulopathy (C3G). Developing therapeutics—ranging from gene therapies to recombinant proteins and small molecule modulators—demands highly characterized, structurally intact target proteins and cofactors.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CFI drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CFI Recombinant Protein HEK293 expressed (Native Glycosylation), heterodimeric assembly (heavy/light chains), High Purity (>95%), Endotoxin Controlled. Sequence Verified. |
View CFI Products |
| Gene Delivery | CFI Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View CFI Products |
| Benchmark Ab | Anti-CFI Antibody Recombinant positive control for ELISA, Western Blot, and functional blocking assays. |
View CFI Products |
| Validator | CFI siRNA Set Target-specific knockdown verification in primary cells or cell lines. |
View CFI Products |
| Related Target A | CFH (Complement Factor H) Essential soluble cofactor required for CFI-mediated cleavage of C3b. |
View CFH Products |
| Related Target B | C3 (including C3b) The primary physiological substrate for CFI proteolytic activity. |
View C3 Products |
| Related Target C | CD46 (MCP) Membrane-bound cofactor mediating CFI cleavage of cell-associated C3b/C4b. |
View CD46 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimeric Folding & Glycosylation | HEK293 mammalian expression system ensures correct disulfide-linked heavy and light chains with native post-translational modifications. |
| Reconstitution of Cleavage Cascade | High-purity cofactor panels (CFH, CD46) available to assemble functional in vitro C3b/C4b degradation assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-potency siRNA sets included for assay validation. |
| False Positives / Protease Contamination | Rigorous purity chromatography (>95% by SDS-PAGE) eliminates trace protease contaminants that interfere with activity assays. |
Live CFI R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CFI is rapidly evolving. While historical complement drug discovery focused on downstream inhibition (e.g., C3 or C5 blockers), modern strategies emphasize restoring homeostatic control via CFI augmentation. Gene therapy represents the leading edge of this wave, aiming to deliver sustained CFI expression directly to the retina to treat geographic atrophy. Concurrently, recombinant CFI proteins are being developed as enzyme replacement therapies for systemic deficiencies, while small molecule positive allosteric modulators are emerging to boost endogenous CFI activity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Novartis (Gyroscope Therapeutics), Roche | Geographic Atrophy (GA), Dry AMD | Expression quantification & functional validation (Need high-purity CFI & CFH) |
| Recombinant Protein | Gemini Therapeutics, Apellis Pharmaceuticals | CFI Deficiency, aHUS, C3G | Pharmacokinetic (PK) assays & activity profiling (Need benchmark antibodies & substrates) |
| Small Molecule / Modulator | Systemic Pharma Players | Complement-mediated renal diseases | High-throughput screening of enzymatic activity (Need stable CFI-C3b-CFH complex reagents) |